American Association for Cancer Research

Program

Bookmark and Share

 

New Horizons in Cancer Research 2011


Program as of December 16

* - Short talks from proffered papers

 

TUESDAY, DECEMBER 13

Opening Session

12:00 p.m.-1:30 p.m.

Welcome and Opening Remarks
Judy Garber, President, American Association for Cancer Research, Philadelphia, PA, USA; Dana-Farber Cancer Institute, Boston, MA, USA
Margaret Foti, American Association for Cancer Research, Philadelphia, PA, USA
Anil K. Rustgi, University of Pennsylvania, Philadelphia, PA, USA

Keynote Presentations

  • The state of the science in India
    Maharaj Kishan Bhan, Government of India, Ministry of Science and Technology, New Delhi, India
  • Current and future prospects for HPV vaccination
    Douglas R. Lowy, National Cancer Institute, Bethesda, MD, USA

Break

1:30 p.m.-1:50 p.m.

Concurrent Sessions 1-2

1:50 p.m.-3:20 p.m.

  • Concurrent Session 1: Shared Cyberinfrastructure for Cancer Research and Treatment

    Session Chairperson: Anil Srivastava, Open Health Systems Laboratory at Johns Hopkins Montgomery County Campus, Rockville, MD, USA

    Global cancer grid: Vision and reality
    Anil Srivastava

    Single cell informatics: Applications in stem cells and cancer
    Saumyadipta Pyne, Dana-Farber Cancer Institute, Boston, MA, USA

    caBRAF: A caBIG-BRAF coaction for cancer bioinformatics
    Rajendra Joshi, Bioinformatics Resources & Applications Facility, Centre for Development of Advanced Computing, Pune, India

    Indo-US partnership to accelerate botanicals and biologics drug development for cancer chemoprevention: In silico drug development model *
    Nagi Kumar, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    Discussion

  • Concurrent Session 2: Pancreatic Cancer

    Session Chairperson: Pramod K. Garg, All India Institute of Medical Sciences, New Delhi, India

    Epidemiology, risk factors, and diagnosis of pancreatic cancer
    Pramod K. Garg

    Molecular pathogenesis of pancreatic cancer and precursor lesions: Lessons from mice and men
    Anirban Maitra, John Hopkins University, Baltimore, MD, USA

    Minnelide: A novel therapy for pancreatic cancer
    Ashok K. Saluja, University of Minnesota, Minneapolis, MN, USA

    Assessing therapeutic responses in pancreatic cancer using genetically engineered mouse models *
    Mallika Singh, Genentech, Inc., South San Francisco, CA, USA

    Discussion

Break

3:20 p.m.-3:40 p.m.

Concurrent Sessions 3-4

3:40 p.m.-5:10 p.m.

  • Concurrent Session 3: Lung Cancer

    Session Chairperson: Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA

    Somatic genome alterations in human lung cancers
    Matthew L. Meyerson

    Clinical implications of genome sequencing in lung cancer
    Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO, USA

    Genomic medicine: Therapeutic opportunities for lung cancer in India
    Amit Dutt, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Mumbai, India

    Methylation events in lung cancer: Whole-genome explorations of paired tumor and nontumor clinical samples *
    Nandita Mullapudi, Genotypic Technologies, Bangalore, India

    Discussion

  • Concurrent Session 4: Cancer Genetics

    Session Chairperson: Curtis C. Harris, National Cancer Institute, Bethesda, MD, USA

    Inflammation and cancer: Interweaving microRNA, innate immune, and p53 networks
    Curtis C. Harris

    Nuclear organization: Effect of chromosome dosage?
    Kundan Sengupta, Indian Institute of Science Education and Research, Pune, India

    Mechanism of chromosomal translocations in leukemia and lymphoma
    Sathees Raghavan, Indian Institute of Science, Bangalore, India

    Epigenetic regulation during glioma development
    Kumaravel Somasundaram, Indian Institute of Science, Bangalore, India

    Discussion

Meet-the-Expert Sessions 1-2 (concurrent)

5:15 p.m.-6:15 p.m.

Session 1: A role of natural products in the discovery of antitumor drugs such as Taxol
Susan Band Horwitz, Albert Einstein College of Medicine, Bronx, NY, USA

Session 2: Microenvironment in hematological malignancies
Varsha Gandhi, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Day in Review

6:20 p.m.-6:45 p.m.
Anil K. Rustgi, Pramod K. Garg, Curtis C. Harris, Matthew L. Meyerson, and Anil Srivastava

Opening Reception

6:45 p.m.-8:30 p.m.

WEDNESDAY, DECEMBER 14

Panel Discussion: Drug Development and Clinical Trials in India

Session Co-Chairpersons: Lalit Kumar, All India Institute of Medical Sciences, New Delhi, India; and Pankaj Bhargava, Sanofi-Aventis, Cambridge, MA, USA
8:00 a.m.-9:30 a.m.

Opening remarks and introductions
Lalit Kumar

Drug development in India: Setting the stage
Pankaj Bhargava

"Fly by night" trials: Ethical concerns in clinical trials
Raghunadharao Digumarti, Nizams Institute of Medical Sciences, Hyderabad, India

Translational endpoints in clinical trials
Sanjeeva Reddy, Endo Pharmaceuticals, Chadds Ford, PA, USA

Developing oncology drugs in India: The Biocon Experience
Kiran Mazumdar-Shaw, Biocon Limited, Bangalore, India

Panel Discussion:

  • Pankaj Bhargava
  • Raghunadharao Digumart
  • Yogendra Kumar Gupta, All India Institute of Medical Sciences, New Delhi, India
  • Lalit Kumar
  • Kiran Mazumdar-Shaw
  • Arvind Pandey, National Institute of Medical Statistics, New Delhi, India
  • Sanjeeva Reddy

Break

9:30 a.m.-9:50 a.m.

Plenary Session 1: Cancer Genomics

Session Co-Chairpersons: Rajiv Sarin, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Hospital, Parel, Mumbai, India; and Ashok R. Venkitaraman, University of Cambridge, Cambridge, United Kingdom
9:50 a.m.-11:40 a.m.

Novel, founder, and recurrent germline mutations in high-penetrance cancer genes in South Asians
Rajiv Sarin

Genomic alterations in gingivobuccal cancer: Results from whole-exome resequencing
Partha P. Majumder, Indian Statistical Institute, Kolkata, India

Interrogating the architecture of cancer genomes
Peter J. Campbell, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom

Exploiting tumor suppressor mechanisms that control genome stability in new approaches to cancer therapy
Ashok R. Venkitaraman

Genome and transcriptome landscape of oral tongue squamous cell carcinoma along with matched potentially malignant lesions *
Binay Panda, Ganit Labs, Bio-IT Centre, Institute of Bioinformatics & Applied Biotechnology, Strand Life Sciences, Bangalore, Karnataka, India

Discussion

Poster Session A/Lunch

11:40 a.m.-1:40 p.m.

Plenary Session 2: Oral and Head/Neck Cancer

Co-Chairpersons: E. Hemanth Raj, Apollo Specialty Hospital, Chennai, India; and Tanuja Teni, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Mumbai, India
1:50 p.m.-3:40 p.m.

Therapeutic targeting of critical pathways in head and neck cancer
Jennifer Rubin Grandis, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Radiation response-related proteins in oral squamous cell carcinomas
Tanuja Teni

Therapy: Surgery
Anil K. D'cruz, Tata Memorial Hospital, Mumbai, India

Therapy: Radiation
A. Vasanthan, Cancer Institute, Adyar, Chennai, India

Discussion

Break

3:40 p.m.-4:00 p.m.

Plenary Session 3: Cervical Cancer

Session Co-Chairpersons: Douglas R. Lowy, National Cancer Institute, Bethesda, MD, USA; and Rita Mulherkar, Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, India
4:00 p.m.-5:50 p.m.

Descriptive epidemiology and prevention of cervical cancer
Rajaraman Swaminathan, Cancer Institute, Adyar, Chennai, India

Transcriptional targeting in cervical cancer
Bhudev C. Das, Dr. B.R. Ambedakar Centre for Biomedical Research, University of Delhi, New Delhi, India

Genomics of cervical cancer
Rita Mulherkar

Treatment of cervical cancers: Modern approaches
Shyam Shrivastava, Tata Memorial Hospital, Mumbai, India

HPV16 E2 potentiates NF-κB activation induced by TNF-α through STAT3 *
Devarajan Karunagaran, Indian Institute of Technology Madras, Chennai, Tamilnadu, India

ADXS11-001 immunotherapy targeting HPV-E7: Preliminary safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer *
Partha Basu, Chittaranjan National Cancer Institute, Kolkata, India

Discussion

Day in Review

5:50 p.m.-6:20 p.m.
Anil K. Rustgi, Rita Mulherkar, Tanuja Teni, and Ashok R. Venkitaraman

Professional Advancement Session: Networking Roundtables

6:30 p.m.-7:45 p.m.

  • Advanced laboratory techniques: Advances in PCR techniques
    Amit Dutt
  • Advanced laboratory techniques: Genomics and microarrays
    Matthew Meyerson
  • Advanced laboratory techniques: Working with cell lines
    Sharmila Bapat, Andrew Dannenberg
  • Biomarkers in oncology: How to set up a biomarker study
    Sanjeeva Reddy
  • Career development in industry
    Sandeep Gupta
  • Career development in universities
    Atul Sharma, Ashok Saluja
  • Careers in translational research
    Annapoorni Rangarajan, Judy Garber
  • Grant writing: Basic/Translational
    Myles Brown, Varsha Gandhi
  • Grant writing: Clinical/Translational
    Aniban Maitra
  • How to become a clinical trialist
    Yves DeClerck
  • How to get the most out of your predoctoral experience
    Xifeng Wu
  • Leadership skills
    Jennifer Grandis, Anil D'Cruz
  • Manuscript writing
    Lalit Kumar, Anil Rustgi
  • Mentoring and supervising
    Mohandas Mallath, Susan Band Horwitz
  • Publication strategies
    Pramod Garg, Curtis Harris
  • Research opportunities for women scientists in India
    Rita Mulherkar
THURSDAY, DECEMBER 15

Panel Discussion: Tobacco: Cancer, Chronic Diseases, and Prevention in India

Session Chairperson: Ellen R. Gritz, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
8:00 a.m.-9:30 a.m.

Introduction
Ellen R. Gritz

Tobacco and cancer epidemiology in India
Prakash C. Gupta, Healis-Sekhsaria Institute for Public Health, Mumbai, India

The adverse disease effects of smoking and smokeless tobacco on tuberculosis in India
Nevin C. Wilson, International Union Against Tuberculosis and Lung Disease (The Union), New Delhi, India

A tree-top tour of tobacco control interventions in LMIC
Mira C. Aghi, Behavioral Scientist, Communication Expert, New Delhi, India

Discussion

Break

9:30 a.m.-10:00 a.m.

Plenary Session 4: Breast Cancer

Session Co-Chairpersons: Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA, USA; and Annapoorni Rangarajan, Indian Institute of Science, Bangalore, India
10:00 a.m.-11:50 a.m.

Clinical genetics and genetic testing
Judy E. Garber

Epigenetics of hormone dependence
Myles Brown, Dana-Farber Cancer Institute, Boston, MA, USA

Gene expression signatures in various categories of breast cancer in Indian patients
Paturu Kondaiah, Indian Institute of Science, Bangalore, India

In vitro transformation of mammospheres generates invasive ductal adenocarcinomas harboring breast cancer cells
Annapoorni Rangarajan

TMEPAI: A novel drug target in breast cancer therapy and prevention *
Prajjal Kanti Singha, University of Texas Health Science Center, San Antonio, TX, USA

Acquisition of oxidative stress resistance during the genesis of luminal mammary progenitors is associated with a switch in ROS control mechanisms *
Nagarajan Kannan, Terry Fox Laboratory, Vancouver, BC, Canada

Discussion

Poster Session B/Lunch

12:00 p.m.-2:00 p.m.

Plenary Session 5: Cancer Prevention and Chemoprevention

Session Co-Chairpersons: Raymond N. DuBois, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; and Ravi Kant, Maulana Azad Medical College, New Delhi, India
2:10 p.m.-3:40 p.m.

Screening for cervical cancer in low- and middle-income countries
Surendra Shastri, Tata Memorial Hospital, Mumbai, India

Prostaglandin E2 promotes intestinal tumor growth via DNA methylation
Raymond N. DuBois

Treating tobacco dependence in the oncology setting: A prevention viewpoint
Ellen R. Gritz, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

A Raman spectroscopy approach for classification of subsites in oral cancers: A feasibility study *
Aditi Sahu, ACTREC-TMC, Navi Mumbai, Maharashtra, India

Discussion

Break

3:40 p.m.-4:00 p.m.

Plenary Session 6: Gallbladder Cancer

Session Chairperson: Pramod K. Garg, All India Institute of Medical Sciences, New Delhi, India, and Xifeng Wu, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4:00 p.m.-5:30 p.m.

Epidemiology of gallbladder cancer in India
Mohandas Mallath, Tata Memorial Hospital, Mumbai, India

Genetics and molecular pathogenesis of gallbladder cancer
Balraj Mittal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Chemotherapy in gallbladder cancer: Is it really needed?
Atul Sharma, All India Institute of Medical Sciences, New Delhi, India

Relationship between various biochemical, hematological, comorbid, lifestyle, and demographic parameters in gallbladder carcinoma: A single-center retrospective study of 342 patients *
Rajeev Kumar, Cachar Cancer Hospital & Research Centre, Silchar, Assam, India

Discussion

Day in Review

5:30 p.m.-6:00 p.m.
Anil K. Rustgi, Raymond N. DuBois, Judy E. Garber, and Lalit Kumar

FRIDAY, DECEMBER 16

Meet-the-Expert Sessions 3-4 (concurrent)

8:00 a.m.-9:00 a.m.

Session 3: Obesity, inflammation, and breast cancer
Andrew J. Dannenberg, Weill Medical College of Cornell University, New York, NY, USA

Session 4: Molecular epidemiology of cancer: Towards personalized risk assessment, prevention, and therapy
Xifeng Wu, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Plenary Session 7: Chronic Myelogenous Leukemia

Session Co-Chairpersons: Lalit Kumar, All India Institute of Medical Sciences, New Delhi, India; and Hemant Malhotra, Sawai ManSingh Medical College, Jaipur, India
9:30 a.m.-11:00 a.m.

Role of miRNAs in CML
Soumen Chakraborty, Institute of Life Sciences, Bhubaneswar, Orissa, India

Is CML epidemiology and natural history different in India?
Kumar Prabhash, Tata Memorial Hospital, Mumbai, India

The future of CML in India
Hemant Malhotra

Influence of hOCT1 (SLC22A1) pharmacogenetics on imatinib mesylate disposition in chronic myeloid leukemia (CML) Asian patients *
Balram Chowbay, National Cancer Centre, Singapore

Targeting of Fyn induction by oxidative stress is an effective strategy for overcoming kinase inhibitor resistance in chronic myeloid leukemia and treating blast crisis *
Joya Chandra, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Discussion

Poster Session C/Lunch

11:00 a.m.-1:00 p.m.

Plenary Session 8: Tumor Microenvironment and Metastasis

Session Co-Chairpersons: Yves A. DeClerck, University of Southern California, Children's Hospital, Los Angeles, CA, USA; and Sudhir Krishna, National Centre for Biological Sciences, Bangalore, India
1:10 p.m.-2:40 p.m.

EMT-MET in ovarian cancer: Metastable states or distant molecular classes?
Sharmila A. Bapat, National Centre for Cell Science, Pune, India

Exploring the cross talk between Notch and Smad3 in EMT, induction of CD66+ cells, and human cervical cancer progression
Sudhir Krishna

Bone marrow mesenchymal stem cells and cancer progression in neuroblastoma
Yves A. DeClerck

Leptin-induced breast cancer growth and metastasis: Functional interactions between leptin signaling, metastasis-associated protein 1(MTA1), and Wnt1 signaling components *
Dipali Sharma, Johns Hopkins University, Baltimore, MD, USA

Role of tumor microenvironment in the induction of melanoma subpopulations *
Raj Somasundaram, The Wistar Institute, Philadelphia, PA, USA

Discussion

Day in Review

2:40 p.m.-3:10 p.m.
Anil K. Rustgi, Hemant Malhotra, and Yves A. DeClerck

Concluding Remarks and Departure

3:10 p.m.-3:30 p.m.